Related Experiment Video

Updated: Jun 15, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway

Chun-Hui Wang1, Cheng-Wei Tang, Chun-Lun Liu

  • 1Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

World Journal of Gastroenterology
|September 13, 2003
PubMed
Abstract

Insights

Octreotide significantly inhibits gastric adenocarcinoma growth by impacting the MAPK pathway. This study reveals its potential as a therapeutic agent for gastric cancer by reducing tumor proliferation and key molecular signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Somatostatin analogues show potential in suppressing various tumor cell growth.
  • The specific impact of octreotide on gastric adenocarcinoma remains largely uninvestigated.

Purpose of the Study:

  • To determine if octreotide inhibits gastric adenocarcinoma growth.
  • To elucidate the probable mechanisms by which octreotide affects gastric cancer.

Main Methods:

  • Assessed gastric cancer cell proliferation using (3)H-thymidine incorporation.
  • Utilized orthotopic xenografts in nude mice treated with octreotide for 8 weeks.
  • Analyzed somatostatin receptor mRNA, extracellular signal-regulated protein kinase (ERK), c-Fos protein levels, and activator protein-1 (AP-1) binding activity.

Main Results:

  • Octreotide significantly reduced SGC-7901 cell proliferation in a dose-dependent manner.
  • Tumor size and weight were significantly decreased in vivo, with a 62.3% inhibition rate.
  • Octreotide decreased ERK and c-Fos protein levels and potentially suppressed AP-1 binding activity, with somatostatin receptors 2 and 3 expressed in cancer cells.

Conclusions:

  • Octreotide demonstrates significant inhibitory effects on gastric adenocarcinoma growth.
  • The mechanism involves the inhibition of sequential molecular events within the MAPK pathway.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...